Results 161 to 170 of about 983 (198)

1023 Solriamfetol and Maintenance of Wakefulness Outcomes in Patients with Narcolepsy and Obstructive Sleep Apnea

Sleep
Patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) struggle to maintain wakefulness. Solriamfetol (Sunosi®) is a dopamine/norepinephrine reuptake inhibitor with agonistic properties at TAAR1
M.J. Thorpy, Graham M L Eglit, S. Floam, Gregory S Parks, Lois Krahn   +4 more
semanticscholar   +1 more source

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm

CNS Spectrums
Craig Chepke, MD: Excel Psychiatric Associates, Huntersville, NC, and Atrium Health, Charlotte, NC; Andrew J. Cutler, MD: SUNY Upstate Medical University, and Neuroscience Education Institute, Syracuse, NY; Samantha Floam, DMD: Axsome Therapeutics, New ...
Craig Chepke, Andrew J Cutler, S. Floam, Gregory S Parks, Russell Rosenberg   +4 more
semanticscholar   +1 more source

Solriamfetol titration and administration (start): Characteristics of patients with narcolepsy and solriamfetol prescriber rationale

Journal of the Neurological Sciences, 2021
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +1 more source

0634 Effects of Solriamfetol on Cognition on Patients with Excessive Daytime Sleepiness Associated with Narcolepsy

Sleep
Previous studies indicated that patients with narcolepsy often exhibit neuropsychological deficits. Cognitive domains related to alertness, attention, executive function, and decision-making are predominantly impaired.
Y. Winter, Geert Mayer, H. Benes, L. Burghaus, Graham M L Eglit, Iresha Abeynayake, S. Floam, Gregory S Parks, U. Kallweit   +8 more
semanticscholar   +1 more source

0970 Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression

Sleep
Psychiatric comorbidities are common in patients with excessive daytime sleepiness (EDS) from narcolepsy or obstructive sleep apnea (OSA). Real-world efficacy and safety data of wake promoting agents in these populations is limited.
U. Kallweit, H. Benes, L. Burghaus, Graham M L Eglit, Iresha Abeynayake, S. Floam, Gregory S Parks, Y. Winter   +7 more
semanticscholar   +1 more source

1024 SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes

Sleep
Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor with agonistic properties at TAAR1 and 5HT1A receptors, is a wake-promoting agent approved to treat excessive daytime sleepiness (EDS) associated with narcolepsy (75–150 mg/day ...
Gregory S Parks, L. Burghaus, Graham M L Eglit, Iresha Abeynayake, S. Floam, Y. Winter   +5 more
semanticscholar   +1 more source

Einstufung von Solriamfetol geändert

NeuroTransmitter, 2021
openaire   +1 more source

Solriamfetol for Excessive Sleepiness in Early-Morning Shift Work Disorder.

NEJM Evidence
BACKGROUND More individuals work early-morning shifts than night shifts, yet investigations into the treatment of shift work disorder (SWD) in this population are lacking.
Kirsi-Marja Zitting, Katherine Gilmore, B. Lockyer, E. B. Leary, Wei Wang, Nicolas Issa, S. F. Quan, Jonathan S. Williams, J. Duffy, C. Czeisler   +9 more
semanticscholar   +1 more source

Summary of opinion: Sunosi,solriamfetol

Case Medical Research, 2019
openaire   +2 more sources

Galenus-Kandidat Solriamfetol - länger wach bei exzessiver Tagesschläfrigkeit

DNP - Der Neurologe & Psychiater, 2021
openaire   +1 more source